We are live on ! Find out more
CBIO

Crescent Biopharma
CBIO

80 hedge funds and large institutions have $123M invested in Crescent Biopharma in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,004% more call options, than puts

Call options by funds: $2.9M | Put options by funds: $263K

0.09% less ownership

Funds ownership: 0.93% → 0.84% (-0.09%)

8% less funds holding

Funds holding: 87 → 80 (-7)

19% less capital invested

Capital invested by funds: $152M → $123M (-$29.1M)

26% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 31

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

Holders
80
Holders Change
-7
Holders Change %
-8.05%
% of All Funds
1.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
23
Reduced
31
Closed
13
Calls
$2.9M
Puts
$263K
Net Calls
+$2.64M
Net Calls Change
+$2.47M

Top Buyers

1
EC
EcoR1 Capital
California
+$7.02M
2
N
Nuveen
North Carolina
+$725K
3
Bank of America
Bank of America
North Carolina
+$709K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$631K
5
CM
Caption Management
Oklahoma
+$570K

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.37M
2
CCM
Camber Capital Management
Massachusetts
-$1.91M
3
Morgan Stanley
Morgan Stanley
New York
-$1.37M
4
Renaissance Technologies
Renaissance Technologies
New York
-$1.25M
5
BCM
Bridgeway Capital Management
Texas
-$691K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCA
76
Berman Capital Advisors
Georgia
$3K – – –
CWC
77
Carolinas Wealth Consulting
North Carolina
$1K – – –
Daiwa Securities Group
78
Daiwa Securities Group
Japan
$1K – – –
PCM
79
Penserra Capital Management
California
$1K +$1.53K +4 New
Millennium Management
80
Millennium Management
New York
– -$496K -1,318 Closed
PP
81
PDT Partners
New York
– -$158K -419 Closed
Walleye Capital
82
Walleye Capital
New York
– -$146K -388 Closed
CI
83
Cigna Investments
Connecticut
– -$100K -268 Closed
FQ
84
First Quadrant
California
– -$99K -264 Closed
SIM
85
Spark Investment Management
New York
– -$91K -245 Closed
Walleye Trading
86
Walleye Trading
New York
– -$71K -189 Closed
SG Americas Securities
87
SG Americas Securities
New York
– -$70K -185 Closed
DTL
88
Dynamic Technology Lab
Singapore
– -$42K -112 Closed
PAG
89
Private Advisor Group
New Jersey
– -$8K -20 Closed
QT
90
Quantbot Technologies
New York
– -$7K -20 Closed
PA
91
Perennial Advisors
New York
– -$4K -10 Closed
Fidelity Investments
92
Fidelity Investments
Massachusetts
– -$2K -6 Closed
1 2 3
4

CBIO Hedge Fund Activity: Q3 2020 in Review

80 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2020, worth a combined $123M — down 19% from $152M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of CBIO and 7 opened new positions — a net loss of 6 holders — while 31 trimmed existing stakes and 23 added.

The largest buyer was EcoR1 Capital, adding an estimated $7.02M. The largest seller was Wellington Management Group, cutting an estimated $3.37M.

  • 80 institutional investors held Crescent Biopharma (CBIO) as of Q3 2020, down from 87 in Q2 2020.
  • Funds reported $123M of Crescent Biopharma stock for Q3 2020, down 19% quarter-over-quarter.
  • 7 funds opened new Crescent Biopharma positions in Q3 2020 and 13 closed out, a net change of -6 holders.
  • The largest Crescent Biopharma buyer in Q3 2020 was EcoR1 Capital, an estimated $7.02M added.
  • The largest Crescent Biopharma seller in Q3 2020 was Wellington Management Group, an estimated $3.37M sold.

Based on aggregated 13F filings for Q3 2020.